Newsylist real-time news trend intelligence
▲ Peaking Business

All eyes on data on Biogen’s tau therapy

Biogen's experimental anti-tau therapy shows promise in slowing cognitive decline for early Alzheimer's patients.

4sources
5articles
3velocity
+0%since first seen
6m agofirst detected

Velocity timeline

How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →

3210Jul 14 16:29Jul 14 18:29 UTC

The brief

Biogen has presented Phase 2 CELIA data at the AAIC, demonstrating that its anti-tau oligonucleotide, diranersen, achieved robust tau reduction and meaningful clinical outcomes. According to STAT, the drug slowed cognitive decline at rates comparable to currently approved therapies.

Coverage from Fierce Biotech, STAT, and AP News emphasizes the drug's potential as researchers seek new approaches to treat Alzheimer's. Biogen reports that these results bolster hopes for the therapy's upcoming pivotal push.

Future attention remains on the progress of this experimental drug as it moves toward further clinical development.

Synthesized by Newsylist from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated just now.

Quick answers

What is the name of the drug being tested?

The anti-tau oligonucleotide is called diranersen.

Where were the results presented?

The Phase 2 CELIA data was presented at the AAIC.

How did the drug perform compared to other therapies?

According to STAT, the study shows the drug slowed decline at rates on par with approved therapies.

Coverage (5)

People, places & organizations

Topics

Related trends

▲ Peaking Health 🔮 holds

The 2 brain-healthy habits a neurologist swears by

Medical experts are highlighting preventable risk factors and specific daily habits to reduce the likelihood of dementia and cognitive decline.

6 sources 6 articles v 4 16h ago